{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension&page=30",
    "query": {
      "intervention": "Open Label Extension",
      "page": 30
    },
    "page_size": 10
  },
  "pagination": {
    "page": 30,
    "page_size": 10,
    "total_count": 2288,
    "total_pages": 229,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension&page=31&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension&page=29&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T17:11:35.650Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06744647",
      "title": "Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Antibody-Mediated Rejection",
        "Kidney Transplantation",
        "Biopsy-proven Histologic Scores",
        "AMR"
      ],
      "interventions": [
        {
          "name": "ALXN2030",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 47,
      "start_date": "2025-03-07",
      "completion_date": "2028-11-07",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-10-27T17:11:35.650Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06744647"
    },
    {
      "nct_id": "NCT01269463",
      "title": "Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder",
        "ADHD"
      ],
      "interventions": [
        {
          "name": "Methylphenidate Hydrochloride Extended Release Capsule",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rhodes Pharmaceuticals, L.P.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "6 Years to 12 Years"
      },
      "enrollment_count": 26,
      "start_date": "2011-01-19",
      "completion_date": "2013-03-13",
      "has_results": true,
      "last_update_posted_date": "2022-12-13",
      "last_synced_at": "2026-10-27T17:11:35.650Z",
      "location_count": 1,
      "location_summary": "Irvine, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01269463"
    },
    {
      "nct_id": "NCT00681863",
      "title": "Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Tourette Syndrome"
      ],
      "interventions": [
        {
          "name": "pramipexole 0.125 mg BID",
          "type": "DRUG"
        },
        {
          "name": "pramipexole 0.0625 mg QD",
          "type": "DRUG"
        },
        {
          "name": "pramipexole 0.125 mg TID",
          "type": "DRUG"
        },
        {
          "name": "pramipexole 0.25 mg BID",
          "type": "DRUG"
        },
        {
          "name": "pramipexole 0.0625 mg BID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 45,
      "start_date": "2008-05",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-05-23",
      "last_synced_at": "2026-10-27T17:11:35.650Z",
      "location_count": 13,
      "location_summary": "Bradenton, Florida • Tampa, Florida • Columbus, Georgia + 9 more",
      "locations": [
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        },
        {
          "city": "Manhasset",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00681863"
    },
    {
      "nct_id": "NCT04051944",
      "title": "A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)"
      ],
      "interventions": [
        {
          "name": "Rozanolixizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB Biopharma SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2019-08-21",
      "completion_date": "2021-11-10",
      "has_results": true,
      "last_update_posted_date": "2022-11-03",
      "last_synced_at": "2026-10-27T17:11:35.650Z",
      "location_count": 4,
      "location_summary": "Scottsdale, Arizona • Augusta, Georgia • Charlotte, North Carolina + 1 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04051944"
    },
    {
      "nct_id": "NCT02391844",
      "title": "Open-Label Study of Oxycodone/APAP to Treat Post-Operative Pain Following Arthroscopic Knee Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Disorder of Knee"
      ],
      "interventions": [
        {
          "name": "Oxycodone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "International Clinical Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 50,
      "start_date": "2014-05",
      "completion_date": "2016-01",
      "has_results": false,
      "last_update_posted_date": "2016-01-07",
      "last_synced_at": "2026-10-27T17:11:35.650Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02391844"
    },
    {
      "nct_id": "NCT00646711",
      "title": "Pediatric Switch Study for Children and Adolescent Patients With Epilepsy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pediatric Epilepsy"
      ],
      "interventions": [
        {
          "name": "Depakote Delayed-Release/Depakote Sprinkle",
          "type": "DRUG"
        },
        {
          "name": "Depakote ER",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abbott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 16,
      "start_date": "2003-02",
      "completion_date": "2003-12",
      "has_results": false,
      "last_update_posted_date": "2008-03-28",
      "last_synced_at": "2026-10-27T17:11:35.650Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00646711"
    },
    {
      "nct_id": "NCT00685399",
      "title": "Safety and Efficacy of AIN457 in Noninfectious Uveitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-infectious Uveitis"
      ],
      "interventions": [
        {
          "name": "AIN457",
          "type": "DRUG"
        },
        {
          "name": "AIN 457",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 76,
      "start_date": "2008-06",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2017-07-17",
      "last_synced_at": "2026-10-27T17:11:35.650Z",
      "location_count": 20,
      "location_summary": "Beverly Hills, California • Los Angeles, California • Sacramento, California + 16 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Golden",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00685399"
    },
    {
      "nct_id": "NCT00607971",
      "title": "Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Constipation-Predominant Irritable Bowel Syndrome"
      ],
      "interventions": [
        {
          "name": "Renzapride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alizyme",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 939,
      "start_date": "2006-04",
      "completion_date": "2008-06",
      "has_results": false,
      "last_update_posted_date": "2008-07-08",
      "last_synced_at": "2026-10-27T17:11:35.650Z",
      "location_count": 126,
      "location_summary": "Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 112 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sierra Vista",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00607971"
    },
    {
      "nct_id": "NCT03369236",
      "title": "A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "C3 Glomerulopathy",
        "C3 Glomerulonephritis",
        "Dense Deposit Disease"
      ],
      "interventions": [
        {
          "name": "Danicopan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "17 Years to 65 Years"
      },
      "enrollment_count": 13,
      "start_date": "2018-06-12",
      "completion_date": "2020-12-18",
      "has_results": true,
      "last_update_posted_date": "2022-10-14",
      "last_synced_at": "2026-10-27T17:11:35.650Z",
      "location_count": 6,
      "location_summary": "Aurora, Colorado • Lawrenceville, Georgia • Iowa City, Iowa + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Lawrenceville",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03369236"
    },
    {
      "nct_id": "NCT07105709",
      "title": "Open-label Extension Study in Participants With Early Alzheimer's Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "GSK4527226",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 220,
      "start_date": "2025-08-14",
      "completion_date": "2028-12-08",
      "has_results": false,
      "last_update_posted_date": "2026-02-02",
      "last_synced_at": "2026-10-27T17:11:35.650Z",
      "location_count": 9,
      "location_summary": "Maitland, Florida • Miami, Florida • Stuart, Florida + 6 more",
      "locations": [
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Stuart",
          "state": "Florida"
        },
        {
          "city": "Toms River",
          "state": "New Jersey"
        },
        {
          "city": "Staten Island",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07105709"
    }
  ]
}